LORAI Health develops a proprietary polymer matrix platform for transdermal drug delivery, focusing on sustained and irritation-free release. The company is targeting the development of a best-in-class estrogen patch for Menopause Hormone Therapy (MHT). This innovation aims to solve issues with current MHT patches, such as poor adhesion and inconsistent hormone delivery.
Funding
Funding not disclosed
Founders
Product
Problem
Menopause symptom management often involves hormone replacement therapy (HRT), but existing delivery methods can be inconvenient, have variable absorption rates, or require frequent administration. This can lead to suboptimal symptom control and reduced adherence to prescribed treatments.
Solution
Lorai Health is developing advanced transdermal patches designed for the sustained delivery of hormonal therapies, specifically targeting the improvement of menopause symptom management. Utilizing proprietary polymer science, the patches aim to provide a more convenient and effective long-term hormone delivery option for women. The technology focuses on personalized care, empowering women to manage their health and well-being during menopause. The patches are designed for long-term use, offering a simplified and consistent method of hormone delivery compared to traditional options.
Target Audience
The primary target audience includes women experiencing menopause and healthcare providers specializing in women's health and hormone replacement therapy.
Features
- Proprietary transdermal patch technology for sustained hormone delivery.
- Designed for convenient and long-term use.
- Focus on personalized menopause care.
- Utilizes advanced polymer science for effective hormone delivery.